App-Quantinova.ai

Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study.

Suzette Delaloge - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Bevacizumab

DECURION: A new model for predicting breast and ovarian cancer risks based on family history using French population incidences and Institut Curies database.

Gregory Nuel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

The 2016 Li-Fraumeni syndrome cancer spectrum.

Olivier Caron - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Li-Fraumeni syndrome

N/A

T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.

Sarina Anne Piha-Paul - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

First things first: Prevention, screening or care?

Francois Eisinger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Mibefradil

Cervical and breast cancer mortality trends in neighboring countries with different screening policies.

Philippe Autier - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cervical cancer

N/A

Breast cancer mortality and mammography screening in Europe, the United States of America, Canada, and Australia.

Cecile Pizot - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Lung cancer risk, diabetes, and diabetes treatments.

Alice Koechlin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.

Wolfgang Wick - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Validation of the new glioma WHO classification in the french POLA network: Analysis of 1041 cases.

Emeline Tabouret - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Glioblastoma

N/A

Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.

Wolfgang Wick - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.

Olivier L. Chinot - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Residual tumor volume and change in tumor volume during adjuvant therapy to predict long-term survival in AVAglio: Phase 3 newly diagnosed glioblastoma patients treated with radiation, temozolomide, and bevacizumab or placebo.

Benjamin M. Ellingson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma.

Aurelie Bertaut - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma.

Khe Hoang-Xuan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).

Martha Nowosielski - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

The ARCAD METACER national cohort study of brain metastases in gastro-intestinal cancers.

Fabienne Portales - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

N/A

Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

David Michael Hyman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Alpelisib

Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers.

Pamela N. Munster - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematologic and solid malignancies

CC-115

Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.

John H. Strickler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

ABBV-399

Filters

24360 Abstracts